secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kezar Life Sciences, Inc. (KZR)
CIK:        0001645666
Form:       8-K
Filed at:   2023-02-28T23:59:59+00:00
Accession:  0000950170-23-005140
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Kezar Life Sciences President & CSO Christopher Kirk resigns; internal promotions announced
--------------------------------------------------------------------------------

- Christopher Kirk, Ph.D. resigns as President and CSO effective April 21, 2023 for personal reasons; will remain on Board as strategic advisor.
- Neel Anand, DPhil promoted to SVP, Research and Drug Discovery; Kieron Wesson, Ph.D. promoted to SVP, CMC and Supply Chain.
- Both new SVPs report to CEO John Fowler as part of the company's succession plan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645666/000095017023005140/0000950170-23-005140-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645666/000095017023005140/kzr-20230227.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-005140

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer